Literature DB >> 26926227

Transplantation in CLL: what we can learn from a dinosaur.

P Dreger1,2, E Montserrat3,4.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 26926227     DOI： 10.1038/bmt.2016.27

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  17 in total

1.  Risk categories and refractory CLL in the era of chemoimmunotherapy.

Authors:  Thorsten Zenz; John G Gribben; Michael Hallek; Hartmut Döhner; Michael J Keating; Stephan Stilgenbauer
Journal:  Blood       Date:  2012-03-06       Impact factor: 22.113

2.  Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus.

Authors:  P Dreger; P Corradini; E Kimby; M Michallet; D Milligan; J Schetelig; W Wiktor-Jedrzejczak; D Niederwieser; M Hallek; E Montserrat
Journal:  Leukemia       Date:  2006-11-16       Impact factor: 11.528

3.  TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial.

Authors:  Peter Dreger; Andrea Schnaiter; Thorsten Zenz; Sebastian Böttcher; Marianna Rossi; Peter Paschka; Andreas Bühler; Sascha Dietrich; Raymonde Busch; Matthias Ritgen; Donald Bunjes; Matthias Zeis; Michael Stadler; Lutz Uharek; Christof Scheid; Ute Hegenbart; Michael Hallek; Michael Kneba; Norbert Schmitz; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Blood       Date:  2013-02-22       Impact factor: 22.113

4.  Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse.

Authors:  M Hahn; S Böttcher; S Dietrich; U Hegenbart; M Rieger; P Stadtherr; A Bondong; R Schulz; M Ritgen; T Schmitt; T H Tran; M Görner; I Herth; T Luft; S Schönland; M Witzens-Harig; T Zenz; M Kneba; A D Ho; P Dreger
Journal:  Bone Marrow Transplant       Date:  2015-07-06       Impact factor: 5.483

5.  Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study.

Authors:  M van Gelder; M H van Oers; W G Alemayehu; M C J Abrahamse-Testroote; J J Cornelissen; M E Chamuleau; P Zachée; M Hoogendoorn; M Nijland; E J Petersen; A Beeker; G-J Timmers; L Verdonck; M Westerman; O de Weerdt; A P Kater
Journal:  Bone Marrow Transplant       Date:  2016-02-15       Impact factor: 5.483

6.  Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Jan A Burger; Kristie A Blum; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Yun Shaw; Elizabeth Bilotti; Cathy Zhou; Danelle F James; Susan O'Brien
Journal:  Blood       Date:  2015-02-19       Impact factor: 22.113

7.  Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.

Authors:  Philip A Thompson; Susan M O'Brien; William G Wierda; Alessandra Ferrajoli; Francesco Stingo; Susan C Smith; Jan A Burger; Zeev Estrov; Nitin Jain; Hagop M Kantarjian; Michael J Keating
Journal:  Cancer       Date:  2015-07-20       Impact factor: 6.860

8.  Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.

Authors:  Mohamed L Sorror; Barry E Storer; Brenda M Sandmaier; Michael Maris; Judith Shizuru; Richard Maziarz; Edward Agura; Thomas R Chauncey; Michael A Pulsipher; Peter A McSweeney; James C Wade; Benedetto Bruno; Amelia Langston; Jerald Radich; Dietger Niederwieser; Karl G Blume; Rainer Storb; David G Maloney
Journal:  J Clin Oncol       Date:  2008-09-15       Impact factor: 44.544

9.  Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: long-term prospective multicenter study.

Authors:  Mauricette Michallet; Gerard Socié; Mohamad Mohty; Mohamad Sobh; Jacques-O Bay; Stéphane Morisset; Hélène Labussière-Wallet; Reza Tabrizi; Noel Milpied; Pierre Bordigoni; Jean El-Cheikh; Didier Blaise
Journal:  Exp Hematol       Date:  2012-10-23       Impact factor: 3.084

10.  Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome.

Authors:  J R Brown; H T Kim; P Armand; C Cutler; D C Fisher; V Ho; J Koreth; J Ritz; C Wu; J H Antin; R J Soiffer; J G Gribben; E P Alyea
Journal:  Leukemia       Date:  2012-08-14       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.